Private company

Harpoon Therapeutics, Inc.

American biological products company based in South San Francisco.

Last updated Oct 18, 2026.

Overview

IndustryBiological Products, (No Diagnostic Substances)
HeadquartersSouth San Francisco, United States
Incorporated inDE²
Business address611 Gateway Boulevard, Suite 400, South San Francisco, Ca 94080²
Filer category, Emerging growth company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-214.1%Operating margin³

-212.2%Net margin³

34.9%Revenue growth, 2022³

-1254.5%Return on equity³

-$89.5MFree cash flow³

Where the money goes

Where each dollar of revenue went, fiscal 2022

Research and development

Research and development100¢$81.4M

Out of $31.9M in revenue.³ The company lost money this year.

Financial statements

Revenue⁴⁵⁶³$31.9M in 2022+4408% since 2017

Operating income⁷⁴⁵⁶³-$68.3M in 2022+513% since 2016

Net income⁷⁴⁵⁶³-$67.7M in 2022+494% since 2016

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Revenue		$708.0K⁴	$4.8M⁵	$5.8M⁶	$17.4M³	$23.7M³	$31.9M³
Research and development	$7.8M⁷	$13.6M⁴	$26.4M⁵	$41.6M⁶	$52.6M³	$72.1M³	$81.4M³
Operating income	-$11.1M⁷	-$16.5M⁴	-$27.7M⁵	-$58.2M⁶	-$51.3M³	-$116.8M³	-$68.3M³
Interest	$261.0K⁷	$285.0K⁴
Income tax		$0⁷	$0⁴	$0⁶	$0³	$0³	$0³
Net income	-$11.4M⁷	-$16.8M⁴	-$27.4M⁵	-$55.6M⁶	-$49.9M³	-$116.7M³	-$67.7M³
Earnings per share					-$1.99³	-$3.62³	-$2.04³
Earnings per share (diluted)					-$1.99³	-$3.62³	-$2.04³

Total assets⁷⁴⁵⁶³$73.7M in 2022+131% since 2017

Total liabilities⁷⁴⁵⁶³$68.3M in 2022+260% since 2017

Shareholders’ equity⁴⁵⁶³$5.4M in 2022

Cash⁷⁴⁵⁶³$51.6M in 2022+5140% since 2016

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Cash	$985.0K⁷	$29.4M⁴	$89.5M⁵	$88.7M⁶	$21.2M³	$44.7M³	$51.6M³
Current assets		$29.6M⁷	$90.2M⁴	$150.6M⁵	$129.8M⁶	$137.7M³	$54.7M³
Total assets		$31.9M⁷	$102.6M⁴	$176.6M⁵	$171.6M⁶	$155.5M³	$73.7M³
Current liabilities		$6.9M⁷	$11.9M⁴	$22.5M⁵	$47.9M⁶	$59.1M³	$52.4M³
Total liabilities		$19.0M⁷	$26.5M⁴	$82.4M⁵	$117.8M⁶	$97.4M³	$68.3M³
Shareholders’ equity	-$10.4M⁴	-$26.9M⁵	-$53.5M⁶	$94.2M³	$53.8M³	$58.1M³	$5.4M³
Shares outstanding		1.2M shares⁷	1.4M shares⁴	24.9M shares⁵	25.6M shares⁶	32.8M shares³	35.8M shares³

Cash from operations⁷⁴⁵⁶³-$89.2M in 2022+726% since 2016

Capital spending⁷⁴⁵⁶³$347.0K in 2022−37% since 2016

Free cash flow⁷⁴⁵⁶³-$89.5M in 2022+689% since 2016

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Cash from operations	-$10.8M⁷	$1.7M⁴	-$27.1M⁵	-$2.9M⁶	-$8.6M³	-$122.2M³	-$89.2M³
Capital spending	$553.0K⁷	$2.3M⁴	$663.0K⁵	$3.5M⁶	$683.0K³	$100.0K³	$347.0K³
Free cash flow	-$11.3M	-$561.0K	-$27.8M	-$6.4M	-$9.3M	-$122.3M	-$89.5M

Compare Harpoon Therapeutics, Inc. with another company

Leadership

Who has led Harpoon Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Chief financial officer

Georgia Erbez2019–2022

20202025

Chief executive officerJulia Marie Eastland Nov 9, 2021 to Mar 11, 2024¹⁰
Chief executive officerGerald McMahon Phd. Feb 7, 2019 to Jan 29, 2021¹¹
PresidentJulia Marie Eastland Nov 9, 2021 to Mar 11, 2024¹⁰
PresidentGerald McMahon Phd. Feb 7, 2019 to Jan 29, 2021¹¹
Chief financial officerGeorgia Erbez Feb 7, 2019 to Feb 1, 2022¹²

Board members and other officers (18)

Principal Fin. & Acctng Ofc.Frank J. Lanza Sep 19, 2022 to Mar 11, 2024¹³
Chief Medical OfficerLuke Nathaniel Walker Oct 4, 2022 to Mar 11, 2024¹⁴
Chief Scientific OfficerHolger Wesche Feb 7, 2019 to Feb 1, 2022¹⁵
Chief Medical OfficerNatalie Sacks Feb 7, 2019 to Feb 1, 2022¹⁶
Board memberLeaf Biopharma Opportunities L.p. New Ii. Mar 11, 2024 to Mar 11, 2024¹⁷
Board memberVijay K. Lathi Mar 11, 2024 to Mar 11, 2024¹⁷
Board memberLauren P. Silvernail Sep 19, 2022 to Mar 11, 2024¹⁸
Board memberAlan Colowick Mar 26, 2021 to Apr 4, 2023¹⁹
Board memberAndrews R. Robbins Apr 1, 2020 to Mar 11, 2024²⁰
Board memberJoseph S. Bailes Apr 1, 2020 to Mar 11, 2024²¹
Board memberJoanne L. Viney Jul 2, 2020 to Apr 4, 2023²²
Board memberGerald McMahon Phd. Feb 7, 2019 to Jan 29, 2021¹¹
Board memberJulia Marie Eastland Feb 7, 2019 to Mar 11, 2024²³
Board memberLuke Evnin Feb 7, 2019 to Jun 1, 2020²⁴
Board memberMark Chin Feb 7, 2019 to Mar 11, 2024²⁵
Board memberPatrick Baeuerle Feb 7, 2019 to Jun 1, 2020²⁶
Board memberScott Dunseth Myers Feb 7, 2019 to Mar 11, 2024²⁷
General counselJames B. Bucher Dec 26, 2023 to Mar 11, 2024²⁸

Timeline

Nov 9, 2021New chief executive Julia Marie Eastland becomes CEO¹⁰
Feb 7, 2019New chief executive Gerald McMahon Phd. becomes CEO¹¹

Filings

201 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 34 major events, 79 insider forms, 29 large holders, 2 private raises, 48 other. The latest 20:

Mar 21, 202415-12G EDGAR
Mar 18, 2024SC 13G EDGAR
Mar 13, 2024SC 13D/A EDGAR
Mar 11, 2024EFFECT EDGAR
Mar 11, 2024EFFECT EDGAR
Mar 11, 2024EFFECT EDGAR
Mar 11, 2024SC 13D/A EDGAR
Mar 11, 2024POS AM EDGAR
Mar 11, 2024POS AM EDGAR
Mar 11, 2024POS AM EDGAR
Mar 11, 2024S-8 POS EDGAR
Mar 11, 2024S-8 POS EDGAR
Mar 11, 2024S-8 POS EDGAR
Mar 11, 2024S-8 POS EDGAR
Mar 11, 2024S-8 POS EDGAR
Mar 11, 2024S-8 POS EDGAR
Mar 11, 2024S-8 POS EDGAR
Mar 11, 20248-K EDGAR
Mar 11, 20244 EDGAR
Mar 11, 20244 EDGAR

The 201 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 29 such filings since October 2021, the latest 10:

Mar 18, 2024SC 13G
Mar 13, 2024SC 13D/A
Mar 11, 2024SC 13D/A
Feb 27, 2024SC 13D
Feb 21, 2024SC 13D/A
Feb 14, 2024SC 13G/A
Feb 14, 2024SC 13G/A
Feb 13, 2024SC 13G/A
Feb 13, 2024SC 13G
Feb 12, 2024SC 13D/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

Oct 25, 2023Raised $100.2 million in a private offering of equity Form D: 18 investors so far Form D
Mar 23, 2023Raised $25 million in a private offering of equity Form D: 6 investors so far Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARHarpoon Therapeutics, Inc. filings on SEC EDGAR
2
SEC EDGARHarpoon Therapeutics, Inc. filings on SEC EDGAR
3
SEC EDGARHarpoon Therapeutics, Inc. 10-K for fiscal 2022
4
SEC EDGARHarpoon Therapeutics, Inc. 10-K for fiscal 2017
5
SEC EDGARHarpoon Therapeutics, Inc. 10-K for fiscal 2018
6
SEC EDGARHarpoon Therapeutics, Inc. 10-K for fiscal 2019
7
SEC EDGARHarpoon Therapeutics, Inc. 10-K for fiscal 2016
8
SEC EDGARHarpoon Therapeutics, Inc. 10-Q for fiscal 2023
9
SEC EDGARHarpoon Therapeutics, Inc. 10-Q for fiscal 2023
10
SEC EDGARJulia Marie Eastland, Chief executive officer
11
SEC EDGARGerald McMahon Phd., Chief executive officer
12
SEC EDGARGeorgia Erbez, Chief financial officer
13
SEC EDGARFrank J. Lanza, Principal Fin. & Acctng Ofc.
14
SEC EDGARLuke Nathaniel Walker, Chief Medical Officer
15
SEC EDGARHolger Wesche, Chief Scientific Officer
16
SEC EDGARNatalie Sacks, Chief Medical Officer
17
SEC EDGARLeaf Biopharma Opportunities L.p. New Ii., Board member
18
SEC EDGARLauren P. Silvernail, Board member
19
SEC EDGARAlan Colowick, Board member
20
SEC EDGARAndrews R. Robbins, Board member
21
SEC EDGARJoseph S. Bailes, Board member
22
SEC EDGARJoanne L. Viney, Board member
23
SEC EDGARJulia Marie Eastland, Board member
24
SEC EDGARLuke Evnin, Board member
25
SEC EDGARMark Chin, Board member
26
SEC EDGARPatrick Baeuerle, Board member
27
SEC EDGARScott Dunseth Myers, Board member
28
SEC EDGARJames B. Bucher, General counsel